Cancer pushes the body’s blood-clotting machinery into overdrive, and the lungs sit directly in the path of the fallout. Tumors release proteins and tiny cell fragments that trick the blood into clotting when it should not, and those clots frequently travel through the veins and lodge in the pulmonary arteries. The result is pulmonary embolism, which occurs in roughly one in every 25 lung cancer patients and is the second leading cause of death among people with cancer overall. The relationship between cancer and clotting is not a side effect or coincidence but a deep biological entanglement that researchers are still working to fully map.
How Tumors Hijack the Clotting System
Blood clotting is a normal repair process. When you cut yourself, a chain reaction of proteins activates to form a plug and stop the bleeding. Cancer cells exploit this system in several ways at once, and understanding these mechanisms explains why clots are so stubbornly common in people with malignancies.
The most studied trigger is a protein called tissue factor. Tissue factor normally lives on the outer surface of cells surrounding blood vessels, where it waits to kick-start clotting if a vessel is damaged. Many tumor cells, however, produce tissue factor on their own surfaces and shed it into the bloodstream on tiny packages called extracellular vesicles. These vesicles circulate far from the original tumor site and activate clotting wherever they land.1PubMed Central. Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer The bloodstream effectively becomes peppered with false wound signals, and the clotting cascade fires in places where no injury exists.2PubMed Central. Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival
A second mechanism involves the immune system’s own defense cells. Neutrophils, a type of white blood cell, can expel webs of their internal DNA to trap bacteria during infection. These structures are called neutrophil extracellular traps, or NETs. Cancer cells hijack this process, stimulating neutrophils to release NETs even when no infection is present.3Thrombosis Research. Neutrophil extracellular traps and cancer-associated thrombosis The sticky webs of DNA act like scaffolding inside blood vessels, catching platelets and clotting proteins and stabilizing clots that might otherwise be cleared. Research in mouse models of lung, breast, and blood cancers has shown that the cancer itself primes neutrophils throughout the body to be more trigger-happy with NET release, and in advanced breast cancer models, the appearance of NETs coincided with venous clots forming in the lungs.4PubMed Central. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis
Tumors can also cause clots through sheer physical pressure. A growing mass in the abdomen or pelvis can lean on nearby veins, slowing blood flow and creating the stagnant conditions that favor clotting. A study of patients with leg and pelvic vein clots found that in all 63 cases examined by imaging, the tumor was directly compressing the vein where the clot formed.5PubMed Central. Iliofemoral Venous Thrombosis Mainly Related to Iliofemoral Venous Obstruction by External Tumor Compression in Cancer Patients These clots in the deep leg and pelvic veins are exactly the ones most likely to break free and travel to the lungs, because the large veins of the lower body feed directly into the pulmonary circulation.6Chest. Pathology of Pulmonary Thromboembolism
Beyond these three routes, abnormal clotting activity can be detected in more than half of all cancer patients and in roughly nine out of ten patients with metastatic disease.7Jornal Brasileiro de Pneumologia. Hypercoagulability and lung cancer The sheer scope of the problem suggests that these are not rare edge-case malfunctions. A hypercoagulable state is closer to the default for an advanced cancer.
Which Cancers Carry the Highest Risk
Not every cancer is equally likely to cause lung clots. Research consistently identifies gastrointestinal, pancreatic, and lung cancers as carrying the greatest clotting risk, with cancer overall increasing the chance of a venous clot by up to seven times compared to someone without a malignancy.8Journal of Clinical Oncology. Pulmonary embolism in cancer patients: Clinical insights and outcomes from a community hospital In one hospital cohort where about a quarter of all pulmonary embolism patients had active cancer, lung cancer accounted for the largest share, followed by gastrointestinal and breast cancers.
Lung cancer has a particularly layered relationship with pulmonary embolism because the tumor sits in the same organ where clots end up. A review of the evidence found a pooled incidence of about 3.7% for diagnosed pulmonary embolism in lung cancer patients. But here is what caught researchers’ attention: when scans done for other reasons happened to catch clots that nobody had suspected, the rate of these “unsuspected” pulmonary embolisms ranged from roughly 29% to 63%.9PubMed Central. Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review That gap between the diagnosed rate and the incidental discovery rate is enormous and suggests that a huge number of lung clots in cancer patients go unnoticed.
Certain genetic features of a tumor also matter. In brain cancers like glioblastoma, specific driver mutations that fuel the tumor’s growth also ramp up the production of clotting proteins on the cell surface. The oncogenes that make a tumor aggressive and the genes that make it prothrombotic are sometimes the same pathways.10Seminars in Thrombosis and Hemostasis. Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis This means clotting risk is not just about cancer type and stage. It is woven into the molecular identity of the tumor itself.
Cancer Treatments That Compound the Problem
The irony of cancer-associated clotting is that many of the treatments used to fight the disease also push clotting risk higher. This is not a rare footnote; it is a well-documented pattern across multiple drug classes.
Tamoxifen, widely used in breast cancer, raises the risk of venous clots by two to seven times. Immunomodulatory drugs used for multiple myeloma, such as thalidomide and lenalidomide, increase clotting risk by roughly 10 to 40% when combined with steroids or other chemotherapy, which is why patients on those regimens routinely receive preventive blood thinners. The platinum-based chemotherapy drug cisplatin and the drug L-asparaginase, used in certain leukemias, are both associated with increased clot formation. Even newer targeted therapies are not exempt: bevacizumab, which blocks the growth of new blood vessels around tumors, raises the risk of arterial clots.11PubMed. Thrombotic Risk from Chemotherapy and Other Cancer Therapies
Supportive medications that manage side effects of cancer treatment add another layer. Drugs that stimulate red blood cell production, growth factor injections for white blood cells, and steroids all carry some thrombotic risk. The picture becomes one of compounding exposures: the cancer itself is prothrombotic, the treatment is prothrombotic, and the patient is often immobilized by illness or recovering from surgery, which slows blood flow and adds yet another risk factor.12PubMed Central. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
Even the hardware of treatment matters. Central venous catheters, the intravenous lines threaded into large veins for delivering chemotherapy, can themselves become sites where clots form. A study comparing catheter types found that peripherally inserted central catheters (PICC lines) carried nearly four times the risk of catheter-related clotting compared to implantable ports.13PubMed Central. Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management A clot that forms on a catheter tip in a vein near the heart is worryingly close to the pulmonary arteries.
Why Clots in the Lungs Are Easy to Miss in Cancer Patients
Pulmonary embolism in cancer patients is frequently diagnosed late, and the reasons are frustratingly practical. The classic warning signs of a lung clot, like sudden shortness of breath, chest pain, cough, or a racing heart, overlap heavily with the symptoms people already experience from their cancer and its treatment. A patient with lung cancer who develops a new cough or worsening breathlessness may have those symptoms attributed to tumor progression, a chest infection, or a treatment side effect. The clot hides behind the noise of an already complicated clinical picture.14PubMed. Delayed Diagnosis in Pulmonary Embolism: Frequency, Patient Characteristics, and Outcome A recent large study confirmed that this overlap is especially problematic when symptoms like coughing match the patient’s underlying cancer diagnosis.15JAMA Network Open. Delayed Venous Thromboembolism Diagnosis and Mortality Risk
There is an even rarer diagnostic trap. Cancer cells themselves can break off from a tumor and embolize to the lungs, mimicking a blood clot. This “tumor embolism” looks nearly identical on the surface: the same breathlessness, the same drop in oxygen. An autopsy study found that while doctors correctly suspected the diagnosis in about 45% of patients who had actual blood clots in their lungs, they identified tumor embolism correctly in only 6% of cases. Most patients with tumor embolism were misdiagnosed as having ordinary blood clots.16American Heart Journal. Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients This matters because the treatment is different: blood thinners help with clots but do nothing for clumps of tumor cells blocking pulmonary vessels.
Trousseau Syndrome and Mucin-Producing Tumors
When clotting problems become the first sign that a cancer exists, oncologists call it Trousseau syndrome. A patient shows up with an unexplained clot, sometimes in an unusual location, and the workup eventually reveals a hidden malignancy. The syndrome spans a range of clotting disorders, from straightforward deep vein thrombosis to a more unusual process involving tiny clots forming in small vessels throughout the body.17PubMed Central. Trousseau’s syndrome: multiple definitions and multiple mechanisms
One specific version of Trousseau syndrome is tied to cancers that produce large amounts of mucin, a thick, gel-like substance. Mucin-rich adenocarcinomas, commonly arising in the pancreas, stomach, and colon, shed mucins into the bloodstream. These circulating mucins interact directly with sticky molecules on the surfaces of platelets and white blood cells, triggering clot formation without even needing the usual thrombin-driven clotting cascade. This mechanism helps explain a long-standing clinical observation: heparin (an anticoagulant that works partly through other pathways) tends to help these patients, while warfarin (which mainly suppresses thrombin production) often does not.18Journal of Clinical Investigation. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas
How Cancer-Associated Lung Clots Are Treated
For decades, the standard treatment for clots in cancer patients was low-molecular-weight heparin, an injectable blood thinner given as a daily shot, often for months. This was inconvenient but worked reasonably well. In recent years, oral blood thinners known as direct oral anticoagulants, or DOACs, have changed the landscape. A meta-analysis of randomized trials found that DOACs reduced recurrent clot events by about a third compared to heparin injections, with no significant difference in overall bleeding risk or mortality.19PubMed. Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Patients With Cancer-Associated Thrombosis: A Meta-Analysis of Randomized Controlled Trials An earlier meta-analysis similarly found DOACs cut recurrent clot risk meaningfully without raising major bleeding rates in observational data, though randomized trial data showed a slight increase in major bleeding.20PubMed. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis
The trade-off is not entirely clean, though. DOACs are taken as pills, which is far more manageable than daily injections, but certain gastrointestinal cancers appear more prone to bleeding complications with oral anticoagulants. This is one of the areas where treatment decisions remain genuinely individualized. A patient with a gastrointestinal tumor and a recent history of bleeding may still be better served by heparin injections, while someone with a different cancer type and no bleeding concerns can usually switch to oral medication.
Predicting Who Will Develop Clots
Given the stakes, oncologists have been trying to predict which patients are most likely to develop clots before one occurs. The best-known tool is the Khorana score, a point-based system that factors in cancer type, blood counts, and body mass index. A systematic review and meta-analysis found that patients scoring three or higher had about an 11% chance of developing a clot within six months, compared to roughly 5% for those scoring zero.21PubMed Central. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis That is useful for identifying a high-risk group that might benefit from preventive blood thinners, but the same analysis highlighted a sobering limitation: most clot events actually occurred in patients who had been classified as low or intermediate risk. Only about 23% of the patients who developed clots within six months had been flagged as high risk.
Newer scoring systems are trying to improve on this. A population-based validation study compared an updated risk score against the Khorana score and found modestly better performance, with the new model achieving stronger discrimination between patients who did and did not develop clots.22Journal of Thrombosis and Haemostasis. Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study Even so, the absolute difference in clot rates between the high-risk and low-risk groups remains small enough that predicting clots with real confidence at the individual level is still out of reach. The field’s honest position is that risk scoring helps guide group-level decisions about preventive treatment but does not reliably tell any single patient whether they will or will not develop a clot.
The Two-Way Street Between Clotting and Cancer Spread
Perhaps the most unsettling aspect of this relationship is that it runs both ways. Clotting does not just happen because of cancer; clotting actively helps cancer spread. When tumor cells break free and enter the bloodstream, they are vulnerable to physical shear forces and immune attack. Platelets coat these circulating tumor cells, forming a protective shell that helps them survive the journey and stick to vessel walls at distant sites. Tumors amplify this process by producing signals that ramp up platelet production in the bone marrow, effectively building themselves a larger supply of bodyguards.23PubMed Central. Platelet first responders in wound response, cancer, and metastasis The same NET webs that promote clotting also trap circulating tumor cells, shielding them and holding them in place long enough to establish new metastatic colonies.
This means that the coagulation system is not a bystander in cancer progression. It is an active participant. Clots are not merely a complication to manage; they are part of the biological infrastructure that tumors use to spread. This insight has raised the question of whether anticoagulant treatment might have anticancer effects beyond just preventing clots, though that idea remains mostly in the research phase.
What Clots Mean for Cancer Prognosis
Developing a blood clot during cancer treatment is a bad prognostic sign. Pulmonary embolism is a high-risk emergency on its own, with sudden death occurring in about a quarter of patients who experience one.24PubMed Central. Life expectancy in cancer patients with pulmonary thromboembolism: From clinical prognostic biomarkers and paraclinical investigations to therapeutic approaches In cancer patients specifically, venous clots are believed to account for roughly 9% of cancer-related deaths. Beyond the direct danger, the development of a clot also serves as a marker that the cancer itself may be behaving more aggressively. Cancer patients who develop clots have higher rates of early death during chemotherapy and poorer outcomes overall compared to cancer patients with the same diagnosis who do not develop clots.25Thrombosis Research. Venous thromboembolism and prognosis in cancer Venous thromboembolism is the second most common cause of death in cancer patients, behind only the cancer itself.26PubMed Central. Thrombosis in cancer patients: etiology, incidence, and management
Whether the clot is independently causing worse outcomes or simply reflecting a more aggressive underlying biology is a question researchers are still parsing. The answer is probably both. A large pulmonary embolism can directly kill by blocking blood flow to the lungs. And a tumor that heavily activates the clotting system may also be one that sheds more cells into the bloodstream and spreads more readily. For the patient, the practical implication is the same: clot prevention and rapid treatment are not optional extras in cancer care but essential components of staying alive long enough for the cancer treatment to work.